June 05, 2026

Chemoimmunotherapy Linked to HNSCC Response

Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.

Conexiant

June 05, 2026

Sleep Study Cutoffs May Guide Discharge

Preoperative sleep study values may distinguish lower-risk children within a population for whom overnight admission is currently routine.

Conexiant

May 14, 2026

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

Conexiant

May 11, 2026

Automated Staining Aids Real-Time Tumor Calls

Automated frozen-section staining helped classify selected ambiguous tumors and margins in a single-center validation study.

Conexiant

May 08, 2026

A Smarter Screen for Sleep Apnea Stimulation

A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation

Conexiant

May 06, 2026

Symptom Scores May Signal Neuropathy Risk

Early recovery symptom patterns may help clinicians identify which oropharyngeal cancer survivors warrant closer neurologic surveillance.

Conexiant

May 01, 2026

Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.

Conexiant

April 30, 2026

Thyroidectomy Appears Safe in Older Patients

Complication differences were statistically higher for some outcomes but small in absolute terms

Conexiant

April 27, 2026

OR Air Setbacks May Not Affect Outcomes

Findings suggest lower ventilation during idle periods may reduce energy use without worsening outcomes.

Conexiant

April 23, 2026

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.

Conexiant